Ebglyss-Lebrikizumab-Lbkz
Ebglyss is used to treat moderate-to-severe atopic dermatitis. It addresses the inflammation caused by eczema all over your body, resulting in persistently dry, itchy, and irritated skin.
Miplyffa-Arimoclomol
Miplyffa is used to treat Niemann-Pick disease type C. The combination of the drug Miplyffa and miglustat is suggested for the treatment of neurological symptoms of Niemann-Pick disease type C in adults as well as children who are at least two years old.
Aqneursa-Levacetylleucine
Aqneursa is an oral granule formulation for patients aged 4 years and older with Niemann‑Pick disease type C. It improves neurological symptoms like coordination and balance by enhancing mitochondrial and lysosomal function and reducing cholesterol buildup in nerve cells.
Cobenfy-Xanomeline And Trospium Chloride
Cobenfy is used to treat schizophrenia. It is the first and only FDA-approved medication for schizophrenia. This drug works by activating muscarinic acetylcholine receptors, which are small proteins in the brain.
Flyrcado-Flurpiridaz F 18
Flyrcado is an IV PET imaging agent for adults with known or suspected coronary artery disease. It highlights blood flow to the heart under rest or stress, helping doctors accurately detect ischemia or areas at risk of infarction.
Itovebi-Inavolisib
Itovebi is an oral targeted therapy, added to palbociclib and fulvestrant, for HR-positive, HER2-negative advanced breast cancer with PIK3CA mutations. It inhibits mutant PI3Kα to slow tumor progression and extend progression-free survival.
Hympavzi-Marstacimab-Hncq
Hympavzi is a subcutaneous antibody given to patients aged 12 and older to prevent bleeding episodes in hemophilia A or B without factor inhibitors. It works by inhibiting the tissue factor pathway to reduce the frequency of bleeds.
Voranigo-Vorasidenib
Voranigo is an oral treatment for adults and teens with Grade 2 astrocytoma or oligodendroglioma that carry an IDH1 or IDH2 mutation, used after surgery. It blocks mutant IDH enzymes to slow tumor progression, significantly extending the time before disease worsens
Nemluvio-Nemolizumab-Ilto
Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.
Anktiva-Nogapendekin Alfa Inbakicept-Pmln
Anktiva is the first FDA-approved immunotherapy that activates the immune system to treat BCG-unresponsive non-muscle invasive bladder cancer (CIS), offering some patients a lasting complete response.
